Sobi issues SEK 600 million bond
Swedish Orphan Biovitrum (Sobi) is issuing a five-year, unsecured, bond on the Swedish market amounting to SEK 600 million and will apply for a listing of the bond on NASDAQ OMX Stockholm.
Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. The product portfolio comprises about 45 marketed products as well as projects in the late clinical phase. Key therapeutic areas are inflammation and genetics and metabolism. In 2011, Sobi had revenues of SEK 1.9 billion and around 500 employees. The company’s share is listed on NASDAQ OMX Stockholm.
Sobi is advised by Mannheimer Swartling in the matter. The firm’s team includes Daniel Karlsson and Rasmus Fahlén.